“Contains semaglutide” and “FDA approved” are not interchangeable statements. That distinction is the first thing a credible GLP-1 directory should make visible.
The FDA approves specific drug products for specific uses after reviewing evidence and manufacturing information. Compounded drugs are prepared for patients under federal and state pathways, but the FDA states that compounded drugs are not FDA approved. The agency does not verify their safety, effectiveness, or quality before marketing.
Why the distinction changes the comparison
With a brand-name route, the telehealth service may provide the evaluation and send a prescription to a retail, mail-order, or manufacturer-connected pharmacy. The program fee and drug cost can be separate, and insurance may become the dominant access question.
With a compounded route, many online programs bundle clinical review, the compounded prescription if approved, supplies, and delivery. That can make the cash price easier to understand. It also makes the identity of the pharmacy, the exact formulation and concentration, storage, beyond-use date, and dosing instructions central to the evaluation.
Shortage status is not a permanent permission slip
Federal compounding rules are technical and fact-specific. They can depend on shortage status, pharmacy type, patient-specific needs, and enforcement policy. A seller’s broad claim that compounding is “the same” or automatically allowed should not substitute for the current FDA position and professional advice.
The FDA’s current GLP-1 warning page describes fraudulent labels, shipping and storage issues, dosing errors, adverse events, and the use of salt forms. It also says retatrutide and cagrilintide cannot be used in compounding under federal law because they are not components of FDA-approved drugs and do not qualify for the applicable bulks-list pathways.
Questions for any compounded offer
- What is the exact name, formulation, concentration, and prescribed dose?
- Which licensed pharmacy compounds and dispenses it for my state?
- What appears on the pharmacy label, and whom do I call with a dosing question?
- How is temperature controlled in transit, and what happens after a delay or warm delivery?
- Does the price change with dose or formulation?
- What is the clinician’s reason for this compounded prescription for me?
These questions are not an accusation and they do not tell a patient which route to choose. They are the minimum facts needed to understand what is being offered.
How GLP.directory labels profiles
A “brand” tag means the provider advertises access to an FDA-approved brand when prescribed; it does not mean every visitor qualifies or gets insurance coverage. A “compounded” tag means the provider advertises a compounded path; it does not imply FDA approval or endorse the formulation. Some providers advertise both. The profile links to the source and dates the review.
Compare what is actually in front of you
| Question | FDA-approved product | Compounded product |
|---|---|---|
| Pre-market FDA review | The specific product has an FDA approval and approved labeling | The product is not FDA approved |
| Identity to record | Brand, strength, dosage form, and labeled manufacturer | Compounding pharmacy, active ingredient, formulation, concentration, and directions |
| Price structure | Often program fee plus retail or specialty-pharmacy cost | Often offered as a cash bundle, but inclusions vary |
| Availability check | Prescription, coverage, and pharmacy inventory remain separate | Prescription, lawful dispensing, pharmacy service area, and fulfillment remain separate |
Read the pharmacy label, not the landing-page shorthand
A marketing page may use an ingredient name broadly. The pharmacy label and prescription identify the product the patient actually received. For a compounded injectable, concentration and measurement instructions are material: the FDA has reported adverse events associated with measurement and dosing errors involving compounded semaglutide, as well as reports involving doses beyond approved-product labeling. Questions about a specific label belong with the prescriber and dispensing pharmacy.
Include shipping and beyond-use instructions in the comparison
Price is incomplete when a refrigerated product arrives warm, damaged, late, or without clear instructions. Record what the pharmacy says about storage, transit, delays, replacement, and the date after which the dispensed product should not be used. Do not substitute a directory’s general statement for the product-specific label and pharmacy guidance.
Use precise words in profiles and articles
“Advertises access to” is different from “provides to every patient.” “FDA-approved brand route” is different from “FDA-approved program.” “Compounded” is different from “generic.” These distinctions are why the directory links to the public methodology and shows the route in each provider profile without treating it as a recommendation.
Sources: FDA, “Compounding and the FDA: Questions and Answers” and “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Checked September 10, 2026.
Source ledger
Primary and first-party sources
- U.S. Food and Drug Administrationfda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↗
- U.S. Food and Drug Administrationfda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers ↗
- U.S. Food and Drug Administrationfda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy ↗
These links support specific facts; inclusion is not an endorsement. Terms can change after the review date.
This report is general information, not medical advice. A licensed clinician who knows your history should guide treatment, prescribing, dosing, and switching decisions. Compounded drugs are not FDA approved.